Anti-cancer chemotherapeutic agent inhibits glioblastoma progress and radiation resistance
Glioblastoma is a major mind tumor with dismal survival charges, even after therapy with surgical procedure, chemotherapy and radiation. A small subpopulation of tumor cells -- glioma stem cells -- is answerable for glioblastoma's tumorigenesis, therapy resistance and subsequent tumor recurrence. A collaborative group of neuro-oncology surgeon/scientists -- led by Ichiro Nakano, M.D., Ph.D., College of Alabama at Birmingham, and Maode Wang, M.D., Xi'an Jiaotong College, Xi'an, China -- has found a singular and beforehand unidentified molecular mechanism that maintains glioma stem cells, they usually have examined it as a possible therapeutic goal in glioblastoma , utilizing a novel small molecule inhibitor they designed and synthesized. This worldwide research was launched after they discovered that one other inhibitor for superior cancers, referred to as OTS167, had a adverse consequence in a medical trial. The Nakano laboratory instantly started to research the mol...